Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives.

[1]  L. Heinemann,et al.  The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. , 2007, Contraception.

[2]  K. Schulz,et al.  Surrogate end points in clinical research: hazardous to your health. , 2005, Obstetrics and gynecology.

[3]  F. Rosendaal,et al.  Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. , 2005, Human reproduction.

[4]  A. Hamsten,et al.  Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. , 2004, American journal of obstetrics and gynecology.

[5]  A. Hamsten,et al.  Sex hormoneebinding globulindA surrogate marker for the prothrombotic effects of combined oral contraceptives , 2004 .

[6]  D. Rennie,et al.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. , 2003, Annals of internal medicine.

[7]  S. Kahn,et al.  BEYOND CARRIER PROTEINS Sex hormone-binding globulin is synthesized in target cells , 2002 .

[8]  I. Persson,et al.  Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? , 2002, Acta obstetricia et gynecologica Scandinavica.

[9]  J M Taylor,et al.  Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. , 1998, Statistics in medicine.

[10]  U. Winkler.  Blood coagulation and oral contraceptives. A critical review. , 1998, Contraception.

[11]  F. Harrell,et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[12]  A. Skene,et al.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure , 1997, The Lancet.

[13]  P. Comp.  Thrombophilic mechanisms of OCs. , 1997, International journal of fertility and women's medicine.

[14]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[15]  L A Moyé,et al.  The cardiac arrhythmia suppression trial. Casting suppression in a different light. , 1995, Circulation.

[16]  D G Altman,et al.  The scandal of poor medical research , 1994, BMJ.

[17]  W. Rosner,et al.  Plasma steroid-binding proteins. , 1991, Endocrinology and metabolism clinics of North America.

[18]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[19]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[20]  S. Haffner,et al.  The relationship of sex hormones to hyperinsulinemia and hyperglycemia. , 1988, Metabolism: clinical and experimental.

[21]  G. Medeiros-Neto,et al.  Serum levels of total testosterone and sex hormone binding globulin in hypothyroid patients and normal subjects treated with incremental doses of L-T4 or L-T3. , 1988, Journal of andrology.

[22]  I. Fogelman,et al.  Hormone Binding Globulins and Anticonvulsant Therapy , 1985, Scottish medical journal.

[23]  G. Hammond,et al.  Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. , 1984, Fertility and sterility.

[24]  S. Gershagen,et al.  Changes in the shbg concentration during danazol treatment , 1984, Acta obstetricia et gynecologica Scandinavica. Supplement.

[25]  C. Edwards,et al.  Circulating testosterone, sex hormone binding globulin and prolactin in women with late onset or persistent acne vulgaris , 1982, The British journal of dermatology.

[26]  E. Mammen,et al.  Oral contraceptives and blood coagulation: a critical review. , 1982, American journal of obstetrics and gynecology.

[27]  J. Uriel,et al.  MATERNAL SERUM LEVELS OF SEX STEROID‐BINDING PROTEIN DURING PREGNANCY , 1981, British journal of obstetrics and gynaecology.

[28]  P. Kopelman,et al.  THE EFFECT OF WEIGHT LOSS ON SEX STEROID SECRETION AND BINDING IN MASSIVELY OBESE WOMEN , 1981, Clinical endocrinology.

[29]  Jeremy N. Morris,et al.  W.H.O. COOPERATIVE TRIAL ON PRIMARY PREVENTION OF ISCHÆMIC HEART DISEASE USING CLOFIBRATE TO LOWER SERUM CHOLESTEROL: MORTALITY FOLLOW-UP Report of the Committee of Principal Investigators , 1980, The Lancet.

[30]  Jeremy N. Morris,et al.  W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. , 1980 .

[31]  W. A. Newman Dorland,et al.  Dorland's Illustrated Medical Dictionary , 1974 .

[32]  R. Rosenfield,et al.  Plasma testosterone binding globulin and indexes of the concentration of unbound plasma androgens in normal and hirsute subjects. , 1971, The Journal of clinical endocrinology and metabolism.

[33]  Ulrich Westphal,et al.  Steroid-Protein Interactions , 1971, Monographs on Endocrinology.

[34]  N. Taylor,et al.  Stedman's Medical Dictionary , 1928 .